Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study

Abstract

The use of abatacept as first bDMARD in the treatment of RA was associated with a slight increased risk of cancer overall and particularly non-melanoma skin cancer, compared with other bDMARDs. This potential signal needs to be replicated in other settings.